ArticleAntibiotics (Basel, Switzerland)2021
NDM Production as a Dominant Feature in Carbapenem-Resistant Enterobacteriaceae Isolates from a Tertiary Care Hospital.
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Overcoming resistance barriers: Using the salvage therapy of Ceftazidime-Avibactam and Aztreonam for difficult-to-treat gram-negative infections at a tertiary care hospital in Karachi-A retrospective cohort pilot.Pakistan journal of medical sciences · 2026Article
- Molecular characterization of blaBMC infectious diseases · 2025Article
- Molecular Epidemiology of Carbapenem-ResistantMicroorganisms · 2025Article
- Prevalence of New Delhi Metallo-β-lactamase (blaMolecular biology reports · 2025Article
- Resistance trend in bacteria isolated from corneal ulcers: A retrospective analysis from Pakistan.PloS one · 2025Article
- A NovelAntibiotics (Basel, Switzerland) · 2024Article
- Predominance ofMedicina (Kaunas, Lithuania) · 2024Article
- Article
- Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species andAntibiotics (Basel, Switzerland) · 2024Review
- First Detection of International High-RiskTransboundary and emerging diseases · 2024Article
- Antimicrobial Susceptibility Profiles ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- Multidrug Resistant Enteric Bacteria from Cancer Patients Admitted in Douala Laquintinie Hospital, Littoral Region of Cameroon.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- In Vitro Activity of New β-Lactamase Inhibitor Combinations againstAntibiotics (Basel, Switzerland) · 2023Article
- New Insights in Molecular Mechanisms in Antimicrobial Resistance and Strategies in Anti-Biofilms.Antibiotics (Basel, Switzerland) · 2023Article
- Estimation, Evaluation and Characterization of Carbapenem Resistance Burden from a Tertiary Care Hospital, Pakistan.Antibiotics (Basel, Switzerland) · 2023Article
- Resistance to Some New Drugs and Prevalence of ESBL- and MBL-Producing Enterobacteriaceae Uropathogens Isolated from Diabetic Patients.Life (Basel, Switzerland) · 2022Article
- Characterization of Genomic Diversity among Carbapenem-ResistantMicroorganisms · 2022Article
- Detection of NDM Variants (Infection and drug resistance · 2022Article
- Prevalence and Molecular Characterization of Extended Spectrum β-Lactamase and Carbapenemase-ProducingInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
Abstract
The worldwide spread and increasing prevalence of carbapenem-resistant Enterobacteriaceae (CRE) is of utmost concern and a problem for public health. This resistance is mainly conferred by carbapenemase production. Such strains are a potential source of outbreaks in healthcare settings and are associated with high rates of morbidity and mortality. In this study, we aimed to determine the dominance of NDM-producing Enterobacteriaceae at a teaching hospital in Karachi. A total of 238 Enterobacteriaceae isolates were collected from patients admitted to Jinnah Postgraduate Medical Centre (Unit 4) in Karachi, Pakistan, a tertiary care hospital. Phenotypic and genotypic methods were used for detection of metallo-β-lactamase. Out of 238 isolates, 52 (21.8%) were CRE and 50 isolates were carbapenemase producers, as determined by the CARBA NP test; two isolates were found negative for carbapenemase production by CARB NP and PCR. Four carbapenemase-producing isolates phenotypically appeared negative for metallo-β-lactamase (MBL). Of the 52 CRE isolates, 46 (88.46%) were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.